Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin’s focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the … Read more
